Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on May 30, 2014 4:37pm

190 Views

Post# 22616623

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Lack of communications

Hi all.

Many helpful and great posts this week.

One statement in one of bengtpress's post was "Also, KD is rich beyond imagination. He would never settle for 50 million dollars if he could potentially make billions on a new blockbuster drug. That very ambitious attitude of his is both a strength and a nuisance for retail investors..."

That's what I like to see and it seems to be supported by the Eastern and NGN investments. We really could be sitting on a gold mine in both rvx-208 and Zenith.

Cheers
Toinv

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?